Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian W Dymock

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Future Medicinal Chemistry|September 8, 2016
The rise of epigenetic drug discoveryBrian W Dymock
Expert Opinion on Therapeutic Patents|November 27, 2009
New patented histone deacetylase inhibitorsHaishan Wang, Brian W Dymock
Handbook of Experimental Pharmacology|July 12, 2015
Fluorescent Probes for H2S Detection and QuantificationWei Feng, Brian W Dymock
Future Medicinal Chemistry|August 23, 2016
Recently discovered EZH2 and EHMT2 (G9a) inhibitorsUttara Soumyanarayanan, Brian W Dymock
Expert Opinion on Therapeutic Patents|February 2, 2013
Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012Brian W Dymock, Cheng Shang See
Bioorganic & Medicinal Chemistry Letters|March 17, 2018
Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90)Lianbin Yao, Sten Ohlson, Brian W Dymock
Methods in Enzymology|March 2, 2015
GYY4137, a novel water-soluble, H2S-releasing moleculePeter Rose, Brian W Dymock, Philip K Moore
Frontiers in Microbiology|May 13, 2017
Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human ProteasomeWilfried Moreira, Sridhar Santhanakrishnan, Brian W Dymock, et al.
Future Medicinal Chemistry|October 21, 2014
Selective JAK inhibitorsBrian W Dymock, Eugene Guorong Yang, Yuyi Chu-Farseeva, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2018
Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)Lianbin Yao, Pondy Murugappan Ramanujulu, Anders Poulsen, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Future Medicinal Chemistry|September 8, 2016
The rise of epigenetic drug discoveryBrian W Dymock
Expert Opinion on Therapeutic Patents|November 27, 2009
New patented histone deacetylase inhibitorsHaishan Wang, Brian W Dymock
Handbook of Experimental Pharmacology|July 12, 2015
Fluorescent Probes for H2S Detection and QuantificationWei Feng, Brian W Dymock
Future Medicinal Chemistry|August 23, 2016
Recently discovered EZH2 and EHMT2 (G9a) inhibitorsUttara Soumyanarayanan, Brian W Dymock
Expert Opinion on Therapeutic Patents|February 2, 2013
Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012Brian W Dymock, Cheng Shang See
Bioorganic & Medicinal Chemistry Letters|March 17, 2018
Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90)Lianbin Yao, Sten Ohlson, Brian W Dymock
Methods in Enzymology|March 2, 2015
GYY4137, a novel water-soluble, H2S-releasing moleculePeter Rose, Brian W Dymock, Philip K Moore
Frontiers in Microbiology|May 13, 2017
Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human ProteasomeWilfried Moreira, Sridhar Santhanakrishnan, Brian W Dymock, et al.
Future Medicinal Chemistry|October 21, 2014
Selective JAK inhibitorsBrian W Dymock, Eugene Guorong Yang, Yuyi Chu-Farseeva, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2018
Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)Lianbin Yao, Pondy Murugappan Ramanujulu, Anders Poulsen, et al.
Pageof 5